Colorcon delivers savings, speed and flexibility for pharmaceutical film coating with Opadry QX
The system can be applied over a broad range of process conditions, including those containing temperature-sensitive active ingredients.
Colorcon Inc. is excited to announce an innovative breakthrough for pharmaceutical tablet coating, with the launch of Opadry QX, quick and fleXible film coating. This revolutionary advance greatly reduces production and preparation times, ensuring coating process efficiency and cost savings in all types of equipment, from traditional pans to continuous coating equipment. The system can be applied over a broad range of process conditions and always results in a premium quality finish for tablets, even those containing temperature-sensitive active ingredients.
Jason Teckoe, Senior Manager – Product Development explains: “Colorcon carried out extensive studies that clearly demonstrate the process adaptability of Opadry QX. The results confirm that Opadry QX provides operators with broader latitude to manage critical settings for optimal film coating such as tablet bed temperatures, spray or air flow rates.”
Latest innovation enables rapid build-up for international manufacturing
Kelly Boyer, General Manager, Film Coatings at Colorcon Inc. further notes: “The commercial impact of the process and equipment flexibility offered by Opadry QX means that multinational pharmaceutical companies can easily transition the manufacture of drug products across continents, overcoming challenges often met with equipment differences. Capital investment may also be deferred through more efficient equipment utilization as productivity demand increases."
This latest innovation clearly demonstrates Colorcon’s leadership in bringing to market film coating systems with enhanced functionality along with improved convenience, manufacturing efficiency, cost savings and dependable performance for the pharmaceutical industry.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.